Is Takeda's Consumer Unit 'Agile' Enough To Stretch Outside Japan?
Takeda says spinning off its consumer product portfolio into a wholly owned and independent subsidiary will boost its profile in the sector, but all signs continue to point to the firm's Rx operations as its predominant revenue drivers.
You may also be interested in...
Biopharma financing decreased by 29% in the first quarter of 2017; conversely, M&As set a record, reaching $61.9 billion. The largest alliance of the quarter involved the microbiome.
Takeda will pay $5.2bn to buy Ariad Pharmaceuticals, the developer of one marketed cancer therapy, Iclusig – but the latter firm's US location and operations could be other important draws for the Japanese big pharma, which has previously announced plans to overhaul its own R&D activities.
Deals with TiGenix and Altos add to a growing gastrointestinal pipeline, as the Japanese pharma sees Entyvio and GI, not Velcade and cancer, as its primary growth-driver.